Share |

PARP Inhibitor Active in Ovarian Cancer

ORLANDO — Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.

  1. No comments yet.
  1. No trackbacks yet.

CommentLuv badge
Powered by Yahoo! Answers